Transcriptomics

Dataset Information

3

Therapeutic interference with mTorc1 restricts inflammation-associated and Stat3-dependent gastro-intestinal tumourigenesis in mice


ABSTRACT: Gp130 receptor engagement on neoplastic cells provides a link by which an inflammatory microenvironment facilitates tumour promotion. Although hyperactivation of the gp130-dependent Stat3 signalling node is commonly observed in solid tumours, Stat3 remains a challenging therapeutic target. To mimic excessive Stat3 signalling, we molecularly validate the gp130FF mouse as a preclinical model for inflammation-associated intestinal-type gastric cancer (IGC), with aberrant mammalian target of rapamycin (mTOR) pathway activity as shared feature. Accordingly, administration of the mTorc1 inhibitor RAD001 reversibly reduced IGC burden in gp130FF mice and suppressed colitis-associated cancer in wild-type mice. Since the therapeutic effect of RAD001 occurs independently of Stat3 hyperactivation, which is also dispensable for gp130-dependent engagement of the PI3K/Akt/mTorc1 pathway, we conclude that mTorc1 signalling limits tumour promoting Stat3 activity The mouse whole-genome gene expression profiling was performed on Illumina's MouseWG-6 v2.0 Expression BeadChips for 24 mice, with 8 mice in each group (gp130WT antral tissue, gp130FF unaffected antral tissue and gp130FF tumour tissue).

ORGANISM(S): Mus musculus  

SUBMITTER: Zhengdeng Lei   Patrick Tan  Steve Rozen  Matthias Ernst  Stefan Thiem 

PROVIDER: E-GEOD-35808 | ArrayExpress | 2013-01-29

SECONDARY ACCESSION(S): GSE35808PRJNA152557

REPOSITORIES: GEO, ArrayExpress

altmetric image

Publications


Gastrointestinal cancers are frequently associated with chronic inflammation and excessive secretion of IL-6 family cytokines, which promote tumorigenesis through persistent activation of the GP130/JAK/STAT3 pathway. Although tumor progression can be prevented by genetic ablation of Stat3 in mice, this transcription factor remains a challenging therapeutic target with a paucity of clinically approved inhibitors. Here, we uncovered parallel and excessive activation of mTOR complex 1 (mTORC1) alon  ...[more]

Similar Datasets

2008-12-24 | GSE11819 | GEO
2008-12-24 | E-GEOD-11819 | ArrayExpress
| GSE92598 | GEO
2006-08-01 | GSE4661 | GEO
2018-06-26 | GSE108978 | GEO
| GSE43800 | GEO
2014-08-19 | BIOMD0000000544 | BioModels
2014-08-19 | BIOMD0000000543 | BioModels
2010-05-27 | GSE22009 | GEO
2013-08-10 | E-GEOD-43800 | ArrayExpress